CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 16,577,600 shares, a growth of 25.8% from the October 15th total of 13,179,400 shares. Based on an average daily volume of 6,265,900 shares, the days-to-cover ratio is presently 2.6 days.
CytoDyn Price Performance
Shares of CYDY stock remained flat at $0.12 during trading hours on Friday. The stock had a trading volume of 2,795,684 shares, compared to its average volume of 2,584,065. The stock has a market capitalization of $149.98 million, a PE ratio of -6.06 and a beta of 0.17. CytoDyn has a 1 year low of $0.11 and a 1 year high of $0.42. The business has a 50 day simple moving average of $0.14 and a 200-day simple moving average of $0.15.
CytoDyn (OTCMKTS:CYDY - Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.
About CytoDyn
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
